[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355971-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-355971-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","impact-of-multigene-panel-testing-in-high-risk-uveal-melanoma-patients","Impact of Multigene Panel Testing in High-Risk Uveal Melanoma Patients","","Germline genetic testing is increasingly used in uveal melanoma care, but the best testing strategy for high-risk patients is not well established. This retrospective chart review evaluated outcomes of germline clinical genetic testing in uveal melanoma patients meeting NCCN criteria. Seventy patients underwent mostly large multigene panel testing; 10 UM patients had pathogenic or likely pathogenic variants in known cancer genes, with an overall positive rate of 13% among unrelated individuals. NCCN guidelines aided prioritization and results supported genetic counseling. No association was found between tumor size or stage and germline P/LP variants.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/impact-of-multigene-panel-testing-in-high-risk-uveal-melanoma-patients/355971/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/impact-of-multigene-panel-testing-in-high-risk-uveal-melanoma-patients/355971.png","ImageObject",300,407,{"name":42,"@type":43},"Blitz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the study?","Question",{"text":63,"@type":64},"To evaluate outcomes of germline clinical genetic testing in uveal melanoma patients who met NCCN guidelines for genetic testing.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many patients underwent testing, and how were tests performed?",{"text":68,"@type":64},"Seventy individuals underwent clinical genetic testing, primarily using large multigene panels.",{"name":70,"@type":61,"acceptedAnswer":71},"What proportion of unrelated individuals had pathogenic or likely pathogenic variants?",{"text":72,"@type":64},"Among unrelated individuals, the positive rate was 13% (8/69).",{"name":74,"@type":61,"acceptedAnswer":75},"Did germline pathogenic/likely pathogenic variants relate to tumor size or stage?",{"text":76,"@type":64},"No association was found between tumor size, stage, and germline P/LP variants.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},355971,1790153549,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":119,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","The official journal of  \nINTERNATIONAL FEDERATION OF PIGMENT CELL SOCIETIES · SOCIETY FOR MELANOMA RESEARCH  \nPIGMENT CELL & MELANOMA Research  \nImpact of Multigene Panel Testing in HighRisk Uveal Melanoma Patients  \nLindsey Byrne1,2  | Isabella Gray1,3 | Kaylee Ramsey1,3 | Joseph McElroy4  | Emma Schreiner1,2 | Jenna Wolfe1,2 | Olivia B. Taylor3  | Frederick Davidorf1,3 |  \nColleen M. Cebulla1,3  | Mohamed H. Abdel-Rahman1,2,3   \nDOI: 10.1111/pcmr.70108  \nIf you wish to order reprints of this article, please see the guidelines here  \nSupporting Information for this article is freely available here  \nEMAIL ALERTS  \nReceive free email alerts and stay up-to-date on what is published in Pigment Cell & Melanoma Research – click here  \nSubmit your next paper to PCMR online at [https://submission.wiley.com/journal/pcmr](https://submission.wiley.com/journal/pcmr)  \nSubscribe to PCMR and stay up-to-date with the only journal committed to publishing basic research in melanoma and pigment cell biology  \nAs a member of the IFPCS or the SMR you automatically get online access to PCMR. Sign up asa member today at www.ifpcs.org or [at](at www.societymelanomaresearch.org/)[ www.societymelanomaresearch.org/](at www.societymelanomaresearch.org/)  \nTo take out a personal subscription, please click here  \nPigment Cell & Melanoma Research  \nORIGINAL ARTICLE  OPEN ACCESS   \nImpact of Multigene Panel Testing in High-Risk Uveal Melanoma Patients  \nLindsey Byrne1,2  | Isabella Gray1,3 | Kaylee Ramsey1,3 | Joseph McElroy4 | Emma Schreiner1,2 | Jenna Wolfe1,2 | Olivia B. Taylor3  | Frederick Davidorf1,3 | Colleen M. Cebulla1,3  | Mohamed H. Abdel-Rahman1,2,3   \n1The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, USA | 2Division of Human Genetics, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA | 3Department of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio,  \nUSA | 4Center for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA Correspondence: Lindsey Byrne ([lindsey.byrne@osumc.edu](lindsey.byrne@osumc.edu))  \nReceived: 28 January 2026 | Revised: 5 June 2026 | Accepted: 12 June 2026  \nKeywords: cancer genes | genetic counseling | genetic testing | germline | retrospective | uveal melanoma  \nABSTRACT  \nGermline genetic testing is increasingly incorporated into the care of patients with uveal melanoma, yet optimal testing strategies remain unclear. This study aimed to evaluate the outcome of germline clinical genetic testing in uveal melanoma (UM) patients who met the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing. A retrospective chart review was conducted on UM patients seen in The Ohio State University Cancer Genetics Clinic between 5/1/2021 and 9/19/2025 . Seventy individuals underwent clinical genetic testing, primarily via large multigene panels. Ten UM patients, including two related individuals, had pathogenic or likely pathogenic (P/LP) variants in known cancer genes (BAP1, BRCA1, BRCA2, MBD4, MUTYH, POT1, XRCC2). Among unrelated individuals, the positive rate was 13%(8/69). Excluding carrier genes, the rate was 10.1%(7/69) . Eight patients would have been missed if only tested for BAP1 per American Society of Clinical Oncology (ASCO) 2024 recommendations. There was no association between tumor size, stage, and germline P/LP variants. In summary, NCCN guidelines are useful in the prioritization of UM patients for genetic testing. Additionally, these findings support genetic counseling for multigene panel testing in high-risk uveal melanoma patients. Further studies of the impact of germline variants on UM disease outcome are warranted.  \n1 | Introduction  \nApproximately 12% of unselected UM patients show evidence of a hereditar","cbCaitkRsXUS1sYu","https://ap.wps.com/l/cbCaitkRsXUS1sYu","pdf",769439,"English","# Introduction\n## Study aim and setting\n# Methods\n## Patient selection and testing approach\n# Results\n## Pathogenic/likely pathogenic findings\n## Missed detections and associations\n# Conclusions\n## Implications for NCCN prioritization and counseling","[{\"question\":\"What was the purpose of the study?\",\"answer\":\"To evaluate outcomes of germline clinical genetic testing in uveal melanoma patients who met NCCN guidelines for genetic testing.\"},{\"question\":\"How many patients underwent testing, and how were tests performed?\",\"answer\":\"Seventy individuals underwent clinical genetic testing, primarily using large multigene panels.\"},{\"question\":\"What proportion of unrelated individuals had pathogenic or likely pathogenic variants?\",\"answer\":\"Among unrelated individuals, the positive rate was 13% (8/69).\"},{\"question\":\"Did germline pathogenic/likely pathogenic variants relate to tumor size or stage?\",\"answer\":\"No association was found between tumor size, stage, and germline P/LP variants.\"}]","Impact of Multigene Panel Testing in High-Risk Uveal Melanoma Patients | PDF",1790122031,23,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbe944fb9423e0da293f105e660c9191.webp",983,1291,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e60e6524ca3273b12c1bcd142994f10.webp",982,1290,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d1030e51fe4f5a7eaf626ecc48df0bb.webp",981,1289,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa7d441098054a130e7d1e35154f7bd3.webp",980,1287]